Nintedanibesylate , 10mMinDMSO , 656247-18-6

CAS NO.：656247-18-6

Empirical Formula: C31H33N5O4.C2H6O3S

Molecular Weight: 649.757

MDL number: MFCD26142360

PRODUCT Properties

• Melting point: >233°C (dec.)
• storage temp.: -20°C Freezer
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: Yellow solid.
• color: Light Yellow to Yellow
• InChIKey: MMMVNAGRWOJNMW-FJBFXRHMSA-N
• SMILES: S(O)(=O)(=O)CC.C(/C1C=CC=CC=1)(=C1\C(NC2=CC(C(=O)OC)=CC=C\12)=O)\NC1C=CC(N(C)C(=O)CN2CCN(C)CC2)=CC=1

Description and Uses

Nintedanib esylate is a potent, oral triple angiokinase inhibitor developed by Boehringer Ingelheim that targets proangiogenic and pro-fibrotic pathways mediated by the vascular endothelial growth factor receptor, fibroblast growth factor receptor and plateletderived growth factor receptor families, as well as Src and Flt-3 kinases. It was approved for the treatment of idiopathic pulmonary fibrosis (IPF), a condition in which the lungs become progressively scarred over time, by the US FDA in October 2014 and by the EMA in January 2015. The FDA granted nintedanib esylate fast-track, priority review, orphan product, and breakthrough designations. The drug was also approved by the EMA in November 2014 for treatment of non-small cell lung cancer in combination with docetaxel after first-line chemotherapy.

Nintedanib Esylate is the salt form of Nintedanib, which is angiokinase inhibitor and is used in the treatment of idiopathic pulmonary fibrosis. Also inhibits the process blood vessel formation which may be used to assist in cancer therapy.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338